This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Criteria used to ensure the validity of primary studies
Not stated.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Six studies were used for control group data, four of which were used for effectiveness estimates.
Methods of combining primary studies
For each primary study, the number of patient-years of observation was used to weight the corresponding incidence of further vertebral deformation in both control and treatment groups.
Investigation of differences between primary studies
One study investigated the development of vertebral deformation in previously normal and deformed vertebrae, whilst three others investigated only previously normal vertebrae. The studies had varying follow up periods accounted for in the weighting scheme used in the analysis, and different criteria for fracture (ranging from a 15% reduction in vertebral weight in one study to 20 -25 for another two studies).
Results of the review
The incidence of further vertebral deformation in women with vertebral fractures (untreated) was 33.7/100 patient years (range: 6.3/100 -72.3/100). The reduction in incidence was comparable for each treatment group with a reduction of 60% with HRT and salmon calcitonin, and of 53% (20% chance of fracture) and 58% (20-25% chance of fracture) with intermittent cyclical etidronate therapy.
Measure of benefits used in the economic analysis
The measure of benefits used in the economic analysis was further vertebral fractures avoided at one year.
Direct costs
Quantities of resource use were analysed separately from the costs, based on the drug regimens only. Drug costs were taken from the British National Formulary and were discounted at 6% per annum. It was stated that monitoring costs were not assessed, nor was the reduction in fracture risk at other sites, or the benefits of HRT on cardiovascular disease. The date for costing was not stated.
